- Clinical Trials Arena
Join Our Newsletter - Get important industry news and analysis sent to your inbox – sign up to our e-Newsletter here
X

Novartis reports positive results from Cosentyx trial

Cosentyx is a fully human biologic that directly blocks interleukin-17A (IL-17A). Credit: Silesia711.